[Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU].
Using the cross-over method, the same patients were administered continuous intravenous injections of 5-FU and HCFU, an oral derivative of 5-FU widely used for breast and colon cancer in Japan. The pharmacokinetics of 5-FU in blood of both drugs were then compared. The AUC of the 5-FU concentration in blood of the HCFU 100 mg group tended to be higher than that in the 5-FU 250 mg group and lower than that in the 5-FU 500 mg group. There was, however, no statistically significant difference between the HCFU and 5-FU 250 mg groups (p = 0.3274), or between the HCFU and 5-FU 500 mg groups (p = 0.1921).
Miyauchi
M
M
Division of Breast Surgery, Chiba Cancer Center.
Yamamoto
N
N
Matsumoto
M
M
Shishikura
T
T
Hyakutake
K
K
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D015996:Survival Rate
D000970:Antineoplastic Agents; C017367:carmofur; D005472:Fluorouracil